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Female Sexual
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Why This Topic?
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Learning
Objectives

02

03

04

Review female sexual response
and anatomy/physiology of the
older female adult

Define different types of sexual
dysfunction and risk factors

Review approaches to screening
for sexual dysfunction in the
primary care setting

Discuss practical approaches to
treatment or referral in the
primary care setting

What I Won’t Be
Covering...
●
●
●
●
●
●
●
●

Male sexual dysfunction disorder
Perimenopause or menopausal treatment
STI Screening Guidelines in Older Adults
Issues surrounding surgical menopause
Sexual Dysfunction Treatment Approaches for Trans patients
Sexual Dysfunction Treatment Approaches for Individuals already
taking Hormone Therapy for Gender Affirming Care
Specifics of Physical Therapy Approaches or psychological approaches
Details of Vaginal CO2 Fractional Laser Treatments

I have no disclosures.

Let’s get started...

Sex is
complicated.

Which words
should we
use?

“Many physicians approach this as a largely
biological phenomenon. They are doing a
disservice to the fact that a woman’s sexual
experience is an incredibly complex
phenomenon that is shaped by cultural
scripting, family-of-origin experience,
relationship dynamics as well as biological
factors.”
-Dr. Dennis Sugrue, former president of American
Association of Sex Educators, Counselors, Therapists

Why should clinicians care?
Reviewing the epidemiology
43% of American women report experiencing sexual problems
12% consider the problem so bothersome leading to personal distress

10%
18-44 years

15%

9%

45-64 years

64-85 years

40% of women ages 65-74 report they are sexually active

Studied Stereotypes of Sexuality in Older Adults

Older adults are
Asexual Beings
Sexuality is
something “dirty”
or wrong

Each physical
contact must
lead to
intercourse.

Sexuality comes naturally and
spontaneously- it doesn’t require
skills or communication

monkeybusinessimages

Medicare Annual Wellness visits
mandates that weight loss, fall
prevention, physical activity, cognition,
vision, hearing, and smoking should be
addressed, but there are no requirements
for sexual history.
Why not?

Let’s Hear
From You.
Have any of you had experience
discussing sexual health or sexual
concerns with older female patients?

01
(brief) Anatomy &
Physiology Review

Hypothalamic Pituitary Ovarian Axis
1. Premenopausal
2. Peri-menopausal
3. Menopausal

armandoh.org/menopause

Post-menopausal Changes to Genital Tract
Pelvic Floor
Weakening of multiple
muscle groups

Labial Changes
Loss of labial fat pad,
thinning of labia
minora

Vaginal Mucosa
Pale, decreased
elasticity, thinner
epithelium,
inflammation

Structure
Shortening and
narrowing of vaginal
canal, loss of vaginal
rugae

Non- Linear Female Sexual
Response

Sexual Desire = Motivation to Have Sex
Sexual Arousal = Physiologic Process of arousal
including vaginal lubrication and genital warmt
related to blood flow

Basson R.

02
Female Sexual
Dysfunction

Disorder Subtypes

Types of Female Sexual Dysfunction - DSMV
Female SexualInterest/Arousal Disorder

Substance/medicationinduced dysfunction

Female Orgasmic
Disorder

Genito-pelvic
pain/penetration
disorder

Female Sexual Interest/Arousal Disorder DSMV
A. Lack of, significantly reduced, sexual interest/arousal by at least 3 the following:
a. Absent/reduced interest in sexual activity
b. Absent/reduced sexual/erotic thoughts or fantasies
c. No/reduced initiation of sexual activity
d. Absent/reduced sexual excitement/pleasure during sexual activity in 75-100% of
the time
e. Absent/reduced sexual interest/arousal in response to internal or external
sexual/erotic clues
f. Absent/reduced genital/nongenital sensation during sexual activity 75-100% of
the time
B. Persisted for minimum duration 6 months
C. Symptoms cause clinically significant distress in the individual
D. The dysfunction is not better explained by nonsexual mental disorder or consequence
of severe relationship distress (e.g. IPV), or effects of substance/medication

Female Orgasmic Disorder - DSMV

A. Marked Delay in, marked infrequency of, or absence of
orgasm, or markedly reduced intensity of orgasmic
sensation, in almost all or all occasions of sexual activity.
B. Persisted for minimum duration 6 months
C. Symptoms cause clinically significant distress in the
individual

Genito-Pelvic Pain/Penetration DisorderDSMV
A. The persistent or recurrent presence of one or more of the following symptoms:
a. Difficulty having intercourse
b. Marked vulvovaginal or pelvic pain during intercourse or penetration
attempts
c. Marked fear or anxiety about vulvovaginal or pelvic pain anticipating
during, or resulting from vaginal penetration
d. Marked tensing or tightening of the pelvic floor muscles during attempted
vaginal penetration
B. Persisted for minimum duration 6 months
C. Symptoms cause clinically significant distress in the individual

Substance/Medication-Induced Sexual
Dysfunction - DSMV

A disturbance in sexual function that has temporal relationship with substance
or medication initiation, dose increase, or substance/medication
discontinuation and causes clinically significant distress in the individual.*

*Disturbance is not better explained by an independent sexual dysfunction
disorder.

Other specified sexual dysfunction and
other unspecified sexual dysfunction “The Leftovers”
Distressing symptoms characteristic of a sexual dysfunction that do no meet
criteria of one of the defined categories. Major distinction between other
categories and unspecified sexual dysfunction is whether the clinician
specifies the reason that the symptoms described do not meet the criteria for
one of the other classes.
- Pregnancy Related Sexual Dysfunction
- Menopausal Related Sexual Dysfunction

Vulvovaginal
Atrophy
Urinary
Symptoms

Genitourinary
Syndrome of
Menopause

Recurrent
UTIs

Vaginal Dryness
Burning & Irritation
Decreased lubrication and pain
during intercourse

80% of adults age 65 and older have at least 1
chronic condition, 68% have 2 or more chronic
conditions.

Medical Conditions Affecting Sexual Dysfunction

AAFP, 2015

Medication & Substance Review

1. New medications including OTC medicine and
vitamins
2. Review recently discontinued meds
3. Review patterns of substance use

AAFP. 2015

So now that we know
what we’re up
against...
How do we approach this in the primary care setting>

03
Screening for Sexual
Health Concerns

How do you
ask about this?

“Do you have any concerns about keeping yourself healthy
and safe?”
- “Many women experience concerns about sex. Are you
experiencing any issues?
“Have you been satisfied with the frequency and nature of
your sexual activities?”
- “Has anyone ever coerced or forced you to have sex?”
- Take a Sexual history - do an infection risk assessment.
-

-

Journal of American Geriatrics Society, 2018

PLISSIT
MODEL

AAFP, 2015, Journal Sex Education Therapy

Biopsychosocial
Approach

Biological

Psychological

Meds, hormones,
neurobiology, physical
health, functional
status, aging

Depression, anxiety,
self-image, substance
abuse, hx of sexual
abuse/trauma

Sociocultural

Interpersonal

Upbringing, cultural
norms, expectations,
religious influence

Relationship
status/quality, partner
sexual function, life
stressors

Hint: This may take more than one visit to address. Utilize your behavioral health
colleagues!

Physical Exam (if indicated)

AAFP, Dyspareunia in Women, 2014

04
Treatment
Approaches

Role of Estrogen Therapy
(Level A evidence)
Data from Cochrane Review 2013, >15 RCTs
- Preferred Treatment for genitourinary syndrome of menopause
- Vaginal tablets, gels, creams, and rings appear to be equally effective
- Minimal systemic absorption with initial use of vaginal estrogen → absorption
decreases as epithelium matures
- Low dose vaginal estrogen preferred over low dose systemic estrogen (w/ or w/o
progestin) for tx of women with only vaginal symptoms
- With vasomotor symptoms, low-dose systemic estrogen is most effective for
vasomotor AND dysparenunia related to genitourinary syndrome of menopause

Image from: mintrx

Administration

Risks for Breast & Endometrial Cancer
-

-

-

ACOG Committee Opinion 2016: Women with history of estrogen-dependent
breast cancer experiencing genitourinary symptoms, vaginal estogen (with or
without progestins) should be reserved for patients who are unresponsive
to non-hormonal remedies. Need a discussion with oncologist.
Data does not show increased risk of cancer recurrence among women
currently undergoing treatment for breast cancer.
Systematic Review in peer-reviewed Menopause 2019 (review of 5,593
abstracts) supports use of low-dose vaginal estrogens for treating vulvar and
vaginal atrophy in menopausal women without concomitant progestogen. No
increase endometrial hyperplasia or cancer risk with low-dose unopposed
vaginal estrogens

Selective Estrogen Receptor ModulatorSERM
(Level A evidence)
- Ospemifene (Osphena)- agonist effects on estrogen receptors selectively on genital tract
and antagonist selectively on breast tissue. Has moderate agonist effect on endometrial
tissue
- Approved by FDA in 2013 for systemic treatment of genitourinary syndrome of menopause
- 60mg daily for the “shortest possible duration” Clinical trials for this medication lasted mean
15 months
- Not associated with endometrial cancer of hyperplasia when used continuously for 1 year
- Currently being studied for safe use with estrogen -sensitive cancer
- Can’t be used along with local vaginal estrogen
- Contraindicated in hx of VTE/PE or estrogen-dependent neoplasia

Androgen Therapy - Transdermal Testosterone
(Level B evidence)
-

-

Treatment option for postmenopausal women with sexual interest and
arousal disorder
Short-term transdermal testosterone
Studied in systematic review of 7 RCTs (n = 3,000), 300 mcgm testosterone
transdermal patch vs. placebo
3-6 month trial with assessment of testosterone levels at baseline and repeat
labs after 3-6 weeks of initial use to see levels within normal range for
reproductive age women.
Follow up labs q6 months
Should be discontinued at 6 months if patient doesn’t show a response
Long term safety and efficacy has not been studied
Watching out for hirsutism, acne, virilization (voice deepending, clitoral
enlargement)

Androgen Therapy - Systemic DHEA
(Level A evidence)
-

Tested but has not shown efficacy in
postmenopausal women for treatment
of sexual interest and arousal disorders
2015 Cochrane Review did show
improvement in DHEA versus placebo
but effect was minimal and not all
studies focused on females sexual
dysfunction.

pharmrx

-

-

Antidepressant-induced female sexual
dysfunction
SSRIs with adverse effect of lowered
libido
Mechanism: Norepi-Dopamine Reuptake
Inhibitor
Cochrane Review of women and men
showed addition of moderate dose
buproprion increased desire, arousal,
lubrication, and orgasm
One RCT 2018 of SSRI-induced sexual
dysfunction, pts with higher dose 150mg
BID has stastically significant higher
scores on Female Sexual Function Index
than controls

Buproprion
(Wellbutrin)

Image: drugs.com

What about female Viagra?
Sildenafil Citrate
- Phosphodiesterase Type 5 inhibitor - vasodilating drug
- Evaluated by not approved by the FDA
- Hypothesis: Vasodilation → increased pelvic blood flow, could address female sexual
interest/arousal disorder or orgasmic disorder
- RCTs have been contradictory
- One RCT in 2011 showed benefit in women who used SSRIs in medication-induced
sexual dysfunction (not sexual interest or arousal disorder)
Flibanserin (Addyi) - not approved in post-menopausal women - $$$
Bremelanotide (Vyleesi) - not approved in post-menopausal women -$$$

Patient Education
Intravaginal Prasterone

Genito-Pelvic
Pain and
Penetration
Disorders

Vaginal Self Dilation - Relief of
Vaginismus
Topical Anesthesia with
Lidocaine
Pelvic Floor Physical Therapy*
Botulinum Toxin A
Lubricants
Vaginal CO2 Fractional Laser Tx

Netter’s

-

Psychological
Intervention

-

(Level B evidence)
-

Sexual Skills Training
- Instruction in masturation for
orgasmic disorders
Cognitive Behavioral Therapy
Mindfulness Based Therapy
- Focus on stress reduction, shown to
be effective in sexual interest/arousal
disorder
Couples Therapy
- Improving communication with
partner
Group-based, couples based CBT
- Identifying and changing
dysfunctional beliefs
Trauma Informed Psychotherapy

A few
cases...

Case 1

SR is 71 year old F with PMH of HTN, T2DM on metformin, presenting
for AWV. When asked about her soc hx, she says she has been widowed
for 4 years but started a new relationship with her neighbor. You ask about
any sexual concerns and she says that she had “trouble” having sex with her
new partner?
● How would you approach this?

Case 2

LS is a 65 year old F G3P2103 all SVDs with PMH osteopenia,
coming in because she’s been having pelvic pain with sex. Her
husband hasn’t had any change in libido and its beginning to
cause a problem because every time they has sex it’s really
painful.
How would you approach this patient?

Summary
- Multifactorial Range of Disorders that require an interdisciplinary approach to Female Sexual
Dysfunction. Patients can have more than one concurrent disorder!
-Primary Care doctors are well equipped to explore sexual health history and diagnose female sexual
dysfunction in the clinic
- A biopsychosocial model of sexual health should be applied when gathering history
-There are multiple safe and efficacious treatment modalities with pharmacology, physical therapy,
devices, and psychological approaches to female sexual dysfunction

Resources for More Information on Female
Sexual Health and Referral
● Resources for clinicians
○ American Association of Sexuality Educators, Counselors, and Therapist
www.aamft.org
○ Society for Sex Therapy and Research www.sstarnet.org
○ International Society for the Study of Women’s Sexual Health www.isswsh.org
● Pelvic Physical Therapy - International Pelvic Pain Society www.pelvicpain.org
● Great Books!
○ “Come As You Are” - Emily Nagoski
○ “Come As You Are Workbook” - https://www.amazon.com/Come-You-AreWorkbook-practical/dp/1912854554
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Any Questions?

Thank
You!
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